Price
$0.693
Decreased by -10.00%
Dollar Volume
749.35 K
ADR%
16.28
Earnings Report Date (estimate)
Mar 20, 23 (-0.3)
Market Cap.
50.97 M
Shares Float
28.42 M
Shares Outstanding
73.55 M
Beta
1.19
Price / Earnings
-0.39
BPR
30.61
20D Range
0.30 0.80
50D Range
0.16 1.19
200D Range
0.16 2.79
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 1, 22 -0.34
Increased by +17.07%
-0.38
Increased by +10.53%
Aug 12, 22 -0.40
Increased by +4.76%
-0.38
Decreased by -5.26%
May 5, 22 -0.46
Decreased by -15.00%
-0.39
Decreased by -17.95%
Mar 30, 22 -0.46
Decreased by -15.00%
-0.45
Decreased by -2.22%
Nov 10, 21 -0.41
Decreased by -20.59%
-0.46
Increased by +10.87%
Jul 29, 21 -0.42
Increased by +12.50%
-0.43
Increased by +2.33%
May 6, 21 -0.40
Increased by +38.46%
-0.42
Increased by +4.76%
Mar 17, 21 -0.40
Increased by +41.18%
-0.36
Decreased by -11.11%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-17.84 M
Decreased by -14.27%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-21.31 M
Decreased by -33.71%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-19.04 M
Decreased by -25.35%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-17.89 M
Decreased by -17.79%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-15.61 M
Decreased by -25.54%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-15.94 M
Decreased by -14.71%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-15.19 M
Decreased by -1.20%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-15.19 M
Increased by +3.33%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.